<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737724</url>
  </required_header>
  <id_info>
    <org_study_id>C43-06</org_study_id>
    <nct_id>NCT00737724</nct_id>
  </id_info>
  <brief_title>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</brief_title>
  <official_title>Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Enfermedades Respiratorias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the efficacy of immediate antiretroviral
      therapy versus 2 month deferred anti-Tb therapy upon the clinical course of tuberculosis and
      HIV infection in patients with AIDS and active tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIDS and tuberculosis are two international and national priority public health problems. The
      best time for starting antiretroviral therapy in patients with AIDS and active tuberculosis
      is not clear, despite of the guidelines regarding CD4+ count. The debate surrounding this
      issue is mainly due to the difficulty among adherence of anti-MTb and anti-HIV treatment, the
      pharmacological interaction, the adverse events related to drugs and the risk of inflammatory
      reconstitution syndrome, especially in patients with advanced HIV infection. Moreover, there
      is great debate upon the lack of knowledge of the degree of immune reconstitution throughout
      time against Mtb induced by the anti-HIV therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Other published trials showed definitive expected superiority of Group 1
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to remission of signs and symptoms of active tuberculosis as well as general symptoms.</measure>
    <time_frame>96 wk</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to negative measurement of mycobacterial load in body fluids or affected tissues</measure>
    <time_frame>24 wk</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ cell count increase</measure>
    <time_frame>24 wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoproliferative response to specific antigens against Mtb</measure>
    <time_frame>24 wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to undetectable HIV plasma load; HIV genotype</measure>
    <time_frame>24 wk</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives both, simultaneously antiretroviral therapy and antituberculosis therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simultaneous ARV and antiMTB</intervention_name>
    <description>Receives both, simultaneously antiretroviral therapy and antituberculosis therapy</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>HAART</other_name>
    <other_name>isoniazid</other_name>
    <other_name>Efavirenz</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferred RV and antiMTB treatment</intervention_name>
    <description>Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>HAART</other_name>
    <other_name>isoniazid</other_name>
    <other_name>Efavirenz</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected

          -  &lt; 200 CD4+ cells/mL

          -  Active pulmonary tuberculosis (with or without extrapulmonary involvement)

        Exclusion Criteria:

          -  Meningeal tuberculosis

          -  Unable to attend 96 wk follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Reyes-Terán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Enfermedades Respiratorias</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Investigaciones en Enfermedades Infecciosas</name>
      <address>
        <city>Mexico city</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45235</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.cisidat.org.mx/</url>
    <description>Consortium for HIV/TB Research in Mexico</description>
  </link>
  <reference>
    <citation>Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull World Health Organ. 1992;70(4):515-26. Review.</citation>
    <PMID>1394786</PMID>
  </reference>
  <reference>
    <citation>De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992 Sep 23-30;268(12):1581-7. Review.</citation>
    <PMID>1518113</PMID>
  </reference>
  <reference>
    <citation>Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995 Jan;151(1):129-35.</citation>
    <PMID>7812542</PMID>
  </reference>
  <reference>
    <citation>Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996 Aug 1;157(3):1271-8.</citation>
    <PMID>8757635</PMID>
  </reference>
  <reference>
    <citation>Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1034-8.</citation>
    <PMID>8887603</PMID>
  </reference>
  <reference>
    <citation>Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991 Jan 31;324(5):289-94.</citation>
    <PMID>1898769</PMID>
  </reference>
  <reference>
    <citation>Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med. 2001 Jul 1;164(1):7-12. Review.</citation>
    <PMID>11435232</PMID>
  </reference>
  <reference>
    <citation>Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002 Jan 4;16(1):75-83.</citation>
    <PMID>11741165</PMID>
  </reference>
  <reference>
    <citation>Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998 Jul;158(1):157-61.</citation>
    <PMID>9655723</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005 Jul 22;19(11):1113-24.</citation>
    <PMID>15990564</PMID>
  </reference>
  <reference>
    <citation>de Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med. 2004;55:283-301. Review.</citation>
    <PMID>14746522</PMID>
  </reference>
  <reference>
    <citation>Orlovic D, Smego RA Jr. Paradoxical tuberculous reactions in HIV-infected patients. Int J Tuberc Lung Dis. 2001 Apr;5(4):370-5. Review.</citation>
    <PMID>11334257</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Enfermedades Respiratorias</investigator_affiliation>
    <investigator_full_name>Gustavo Reyes-Teran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Enzyme-Linked ImmunoSpot</keyword>
  <keyword>Deferred treatment</keyword>
  <keyword>Immune Recovery Inflammatory Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Antitubercular Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

